CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin…
In June 2023, Longeveron filed with the SEC to offer subscription rights worth up to $30 million of shares of…
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in…
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs,…
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received a letter from the Listing Qualifications Department of…
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced a…
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today…
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic…
Near Intelligence (NASDAQ: NIR), a global data intelligence platform that curates one of the world’s largest sources of intelligence on…
Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand…